Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 9,887,000 $ 22,676,000
Investments in debt securities 7,599,000 10,845,000
Accounts receivable - trade 1,055,000 1,000,000
Settlement receivable - current portion 5,100,000 5,100,000
Prepaid expenses and other current assets 1,146,000 1,549,000
Current assets held for sale 38,778,000 3,900,000
Total Current Assets 63,565,000 45,070,000
Restricted cash 5,996,000 5,996,000
Noncurrent assets held for sale   37,314,000
Convertible promissory note receivable and accrued interest 1,650,000 1,631,000
Finance lease right-of-use assets, net of accumulated amortization 875,000 74,000
Operating lease right-of-use asset 2,928,000 3,068,000
Fixed assets, net of accumulated depreciation 3,464,000 1,373,000
Intangible assets, net of accumulated amortization 6,013,000 4,851,000
Prepaid expenses - noncurrent 44,000 74,000
Security deposits 29,000 29,000
Total Assets 84,564,000 99,406,000
Current liabilities:    
Accounts payable 4,807,000 4,264,000
Accrued expenses 2,595,000 3,764,000
Finance lease obligations - current portion 303,000 46,000
Operating lease obligation - current portion 183,000 91,000
Current liabilities related to assets held for sale 1,949,000 56,000
Term note payable - net of deferred financing costs 22,201,000 22,161,000
Contract liabilities 161,000 100,000
Total Current Liabilities 32,199,000 30,436,000
Finance lease obligations - net of current portion 576,000 30,000
Operating lease obligation - net of current portion 3,421,000 3,514,000
Noncurrent liabilities related to assets held for sale   1,971,000
Total Liabilities 36,196,000 35,921,000
iBio, Inc. Stockholders' Equity:    
Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2022 and June 30, 2022; 9,006,582 and 8,727,158 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively 9,000 9,000
Additional paid-in capital 290,642,000 287,619,000
Accumulated other comprehensive loss (223,000) (213,000)
Accumulated deficit (242,060,000) (223,930,000)
Total iBio, Inc. Stockholders' Equity 48,368,000 63,485,000
Total Liabilities and Equity $ 84,564,000 $ 99,406,000